The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback